Loading...
XHKG
1349
Market cap110mUSD
May 09, Last price  
2.64HKD
1D
0.00%
1Q
10.92%
Jan 2017
-59.26%
Name

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
7.37
P/S
0.94
EPS
0.33
Div Yield, %
3.69%
Shrs. gr., 5y
2.30%
Rev. gr., 5y
2.82%
Revenues
851m
-17.50%
20,117,00019,764,00024,927,00031,990,00061,905,00092,390,000133,890,000232,527,000415,925,000470,900,000579,463,000621,870,000497,694,000740,422,0001,029,294,769833,802,6931,140,313,0881,031,159,838850,733,212
Net income
109m
-21.28%
-30,356,000-22,030,000-29,550,000-23,402,000-7,320,0003,681,00030,826,00053,159,00087,218,000118,258,000127,723,000138,708,00075,287,000150,982,000227,357,983164,662,782213,295,758137,997,098108,627,368
CFO
71m
-57.03%
-21,399,000-17,185,000-15,890,0007,724,000-7,108,00049,589,000110,188,00089,442,00088,359,00096,296,000140,574,00042,711,000173,939,000269,232,612113,003,294268,899,775165,268,62271,015,450
Dividend
Jul 10, 20250.0321 HKD/sh
Earnings
Jun 27, 2025

Profile

PFC Device Inc., together with its subsidiaries, engages in the research and development, design, manufacture, and sale of power discrete semiconductors under the PFC brand name in China, Hong Kong, Taiwan, and other Asian countries. It offers rectifiers, MOSFETs, IGBTs, bridge rectifiers, and packaging products for general power, consumer, industrial, and automotive applications. The company also provides power supply products; package products for mobile phone charger; and power supply applications for network and communication. In addition, it engages in investment and trade mark holding activities. The company was incorporated in 2016 and is headquartered in Chai Wan, Hong Kong. PFC Device Inc. is a subsidiary of Lotus Atlantic Limited.
URL
http://www.fd-zj.com
IPO date
Aug 13, 2002
Employees
138
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
850,733
-17.50%
1,031,160
-9.57%
Cost of revenue
586,032
878,492
Unusual Expense (Income)
NOPBT
264,701
152,668
NOPBT Margin
31.11%
14.81%
Operating Taxes
(10,922)
(4,979)
Tax Rate
NOPAT
275,623
157,647
Net income
108,627
-21.28%
137,997
-35.30%
Dividends
(76,152)
(71,039)
Dividend yield
2.89%
1.99%
Proceeds from repurchase of equity
9,516
BB yield
-0.27%
Debt
Debt current
6,329
109,216
Long-term debt
28,234
39,414
Deferred revenue
2,153
34,043
Other long-term liabilities
34,043
Net debt
(1,448,866)
(1,447,044)
Cash flow
Cash from operating activities
71,015
165,269
CAPEX
(98,968)
(87,304)
Cash from investing activities
(45,377)
(96,748)
Cash from financing activities
(118,977)
11,608
FCF
232,742
53,865
Balance
Cash
1,195,896
1,289,303
Long term investments
287,533
306,371
Excess cash
1,440,893
1,544,116
Stockholders' equity
1,022,978
981,063
Invested Capital
1,355,019
1,455,207
ROIC
19.62%
11.22%
ROCE
11.13%
6.36%
EV
Common stock shares outstanding
1,034,170
1,031,233
Price
2.55
-26.51%
3.47
-9.87%
Market cap
2,637,135
-26.30%
3,578,378
-11.04%
EV
1,189,278
2,132,454
EBITDA
324,629
233,639
EV/EBITDA
3.66
9.13
Interest
3,066
1,538
Interest/NOPBT
1.16%
1.01%